We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-9.88%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$143M
Cap. Flow
+$317M
Cap. Flow %
20.31%
Top 10 Hldgs %
50.44%
Holding
68
New
13
Increased
28
Reduced
8
Closed
16

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.6M
2
FATE icon
Fate Therapeutics
FATE
+$61.3M
3
AGEN
Agenus
AGEN
+$38.5M
4
BCYC
Bicycle Therapeutics
BCYC
+$35.3M
5
NVCR icon
NovoCure
NVCR
+$33.1M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$23.8M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$17.1M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$11.9M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.24%
2 Real Estate 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
51
Autolus Therapeutics
AUTL
$397M
$1.59M 0.1%
+382,559
New +$1.61M
RFL icon
52
Rafael Holdings
RFL
$101M
$261K 0.02%
105,614
-184,100
-64% -$631K
ACAD icon
53
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-1,000,000
Closed -$23.3M
ALNY icon
54
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-11,700
Closed -$1.98M
ASND icon
55
Ascendis Pharma A/S
ASND
$16B
– –
-80,000
Closed -$10.8M
ATRA icon
56
Atara Biotherapeutics
ATRA
$75.5M
– –
-30,000
Closed -$11.8M
BBIO icon
57
CALL
BridgeBio Pharma
BBIO
$15.7B
– –
-400,000
Closed -$6.67M
CNTA
58
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-400,000
Closed -$4.5M
CNTB
59
Connect Biopharma Holdings
CNTB
$127M
– –
-647,057
Closed -$3.33M
PTGX icon
60
Protagonist Therapeutics
PTGX
$8.79B
– –
-421,660
Closed -$11.9M
RNAM
61
DELISTED
Avidity Biosciences
RNAM
– –
-1,000,000
Closed -$23.8M
SAGE
62
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-400,000
Closed -$17M
VNDA icon
63
CALL
Vanda Pharmaceuticals
VNDA
$307M
– –
-500,000
Closed -$7.84M
VNDA icon
64
Vanda Pharmaceuticals
VNDA
$307M
– –
-500,000
Closed -$7.84M
TECX
65
Tectonic Therapeutic
TECX
$529M
– –
-87,511
Closed -$4.04M
KRTX
66
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-130,200
Closed -$17.1M
ONCR
67
DELISTED
Oncorus, Inc.
ONCR
– –
-600,000
Closed -$3.16M
SRRA
68
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-607,600
Closed -$13.2M
1 2
3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Deep Track Capital held 68 positions worth $1.56B, up 10% from $1.42B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deep Track Capital deployed $317M of net new capital in Q1 2022, opening 13 new positions and adding to 28 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 463,663 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Verve Therapeutics, an estimated $11.4M trimmed.

  • Deep Track Capital's largest Q1 2022 buy was Alnylam Pharmaceuticals: 463,663 shares worth $75.7M.
  • Deep Track Capital added most to Fate Therapeutics in Q1 2022, an estimated $61.3M increase.
  • Deep Track Capital's biggest Q1 2022 reduction was Verve Therapeutics, cutting an estimated $11.4M.
  • Deep Track Capital fully exited Avidity Biosciences in Q1 2022, selling an estimated $23.8M.
  • Deep Track Capital's ten largest holdings make up 50% of its $1.56B portfolio in Q1 2022.
  • Deep Track Capital opened 13 new positions and closed 16 in Q1 2022.
  • Deep Track Capital's portfolio value rose 10% quarter-over-quarter to $1.56B.

Based on Deep Track Capital's 13F filing for Q1 2022, filed 16 May 2022.